Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5965 in PNH Naïve Patients
NCT06051357Phase 2Completed
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-5965 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Chengdu Suncadia Pharmaceuticals. Started Nov 2023; status: completed.
02
Drugs
HRS-5965
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06051357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06051357.